Jane Street
HRTX icon

Jane Street’s Heron Therapeutics HRTX Stock Holding History

Jane Street’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,367,891
Closed -$1.59M – 12165
2025
Q4 		$1.78M Buy
1,367,891
+1,147,583
+521% +$1.42M ﹤0.01% 5036
2025
Q3 		$278K Sell
220,308
-111,078
-34% -$176K ﹤0.01% 9057
2025
Q2 		$686K Buy
331,386
+315,358
+1,968% +$644K ﹤0.01% 6342
2025
Q1 		$35.3K Sell
16,028
-31,799
-66% -$61.7K ﹤0.01% 9068
2024
Q4 		$73.2K Sell
47,827
-284,299
-86% -$461K ﹤0.01% 8871
2024
Q3 		$661K Sell
332,126
-18,776
-5% -$44.8K ﹤0.01% 6693
2024
Q2 		$1.23M Buy
350,902
+82,439
+31% +$253K ﹤0.01% 5387
2024
Q1 		$744K Buy
268,463
+101,867
+61% +$256K ﹤0.01% 5965
2023
Q4 		$283K Buy
166,596
+128,914
+342% +$142K ﹤0.01% 7677
2023
Q3 		$38.8K Sell
37,682
-79,429
-68% -$113K ﹤0.01% 8206
2023
Q2 		$136K Buy
117,111
+73,288
+167% +$131K ﹤0.01% 7860
2023
Q1 		$66.2K Sell
43,823
-257,341
-85% -$644K ﹤0.01% 8369
2022
Q4 		$753K Buy
301,164
+129,711
+76% +$418K ﹤0.01% 5456
2022
Q3 		$724K Buy
171,453
+41,169
+32% +$161K ﹤0.01% 6002
2022
Q2 		$363K Buy
+130,284
New +$523K ﹤0.01% 7282
2022
Q1 		– Sell
-127,575
Closed -$934K – 10593
2021
Q4 		$1.17M Buy
127,575
+71,428
+127% +$729K ﹤0.01% 5586
2021
Q3 		$600K Buy
56,147
+46,085
+458% +$561K ﹤0.01% 6932
2021
Q2 		$156K Sell
10,062
-38,347
-79% -$610K ﹤0.01% 9019
2021
Q1 		$785K Buy
48,409
+20,723
+75% +$369K ﹤0.01% 5933
2020
Q4 		$586K Sell
27,686
-16,636
-38% -$289K ﹤0.01% 5496
2020
Q3 		$657K Buy
44,322
+17,340
+64% +$271K ﹤0.01% 4754
2020
Q2 		$397K Buy
26,982
+13,650
+102% +$224K ﹤0.01% 5414
2020
Q1 		$157K Sell
13,332
-26,380
-66% -$496K ﹤0.01% 4760
2019
Q4 		$933K Buy
39,712
+28,533
+255% +$631K ﹤0.01% 2875
2019
Q3 		$207K Buy
+11,179
New +$206K ﹤0.01% 4606
2018
Q4 		– Sell
-47,737
Closed -$1.51M – 5259
2018
Q3 		$1.51M Buy
47,737
+41,057
+615% +$1.53M ﹤0.01% 2227
2018
Q2 		$260K Sell
6,680
-14,131
-68% -$450K ﹤0.01% 4281
2018
Q1 		$574K Buy
20,811
+2,005
+11% +$45.5K ﹤0.01% 3327
2017
Q4 		$340K Buy
18,806
+5,006
+36% +$81.6K ﹤0.01% 3616
2017
Q3 		$223K Buy
+13,800
New +$216K ﹤0.01% 4016
2016
Q2 		– Sell
-15,643
Closed -$297K – 4291
2016
Q1 		$297K Buy
15,643
+6,486
+71% +$128K ﹤0.01% 3217
2015
Q4 		$244K Buy
9,157
+423
+5% +$11.3K ﹤0.01% 3347
2015
Q3 		$213K Buy
+8,734
New +$291K ﹤0.01% 3127
2014
Q3 		– Sell
-31,145
Closed -$384K – 2758
2014
Q2 		$384K Sell
31,145
-13,615
-30% -$163K ﹤0.01% 1626
2014
Q1 		$622K Buy
+44,760
New +$598K 0.01% 1369

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Jane Street's HRTX Position: Q1 2026 in Review

Jane Street sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 1,367,891 shares — an estimated $1.59M sold.

Jane Street first reported a position in HRTX in Q1 2014 and held it in 35 quarters. The position peaked at $1.78M in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Jane Street reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 1,367,891 Heron Therapeutics shares in Q1 2026, an estimated $1.59M.
  • Jane Street first reported a position in Heron Therapeutics in Q1 2014 and held it in 35 quarters.
  • Jane Street's Heron Therapeutics position peaked at $1.78M in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.